Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [ACA]

ABSTRACT: Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [ACA]

PROVIDER: PRJNA923335 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [ACA]

Project description:We used protein arrays to measure IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in patients with non-COVID-19 infections such as influenza

2023-01-12 | GSE222760 | GEO

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [CTD]

2023-01-12 | GSE222764 | GEO

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness

Project description:Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness

| PRJNA923332 | ENA

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [CTD]

Project description:Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [CTD]

| PRJNA923336 | ENA

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-01-12 | GSE222765 | GEO

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.

Project description:The widespread presence of autoantibodies in acute infection with SARS-CoV-2 is increasingly recognized, but the prevalence of autoantibodies in non-SARS-CoV-2 infections and critical illness has not yet been reported. We profiled IgG autoantibodies in 267 patients from 5 independent cohorts with non-SARS-CoV-2 viral, bacterial, and noninfectious critical illness. Serum samples were screened using Luminex arrays that included 58 cytokines and 55 autoantigens, many of which are associated with connective tissue diseases (CTDs). Samples positive for anti-cytokine antibodies were tested for receptor blocking activity using cell-based functional assays. Anti-cytokine antibodies were identified in > 50% of patients across all 5 acutely ill cohorts. In critically ill patients, anti-cytokine antibodies were far more common in infected versus uninfected patients. In cell-based functional assays, 11 of 39 samples positive for select anti-cytokine antibodies displayed receptor blocking activity against surface receptors for Type I IFN, GM-CSF, and IL-6. Autoantibodies against CTD-associated autoantigens were also commonly observed, including newly detected antibodies that emerged in longitudinal samples. These findings demonstrate that anti-cytokine and autoantibodies are common across different viral and nonviral infections and range in severity of illness.

| S-EPMC9977421 | biostudies-literature

Impaired innate and adaptive immune responses to BNT162b2 SARSCoV-2 vaccination in systemic lupus erythematosus [ACA]

Project description:We measued IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in SLE and healthy controls who received the BNT162b2 vaccine.

2024-03-02 | GSE260475 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [viral]

Project description:We developed three different protein arrays to measure IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers.

2021-07-24 | GSE180742 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Autoantigen V2]

2021-07-24 | GSE180738 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Autoantigen V1]

2021-07-24 | GSE180737 | GEO